Why Did RUM, MRK, NEM Stocks Jump To 52-Week Highs Today?
Rum Group, Merck, and Newmont shares surged to annual highs amid positive company catalysts, Wall Street optimism, and a rise
Why Did RUM, MRK, NEM Stocks Jump To 52-Week Highs Today?Rum Group, Merck, and Newmont shares surged to annual highs amid positive company catalysts, Wall Street optimism, and a rise |
Myriad Genetics and Moderna Shares Plummet, What You Need To KnowA number of stocks fell in the afternoon session after shares across biotech and big pharma cooled further as traders |
A cancer vaccine years in the making just proved itselfMerck added billions in a single day after its Moderna-partnered cancer vaccine cleared a major hurdle. |
Merck & Co. Aktienanalyse: Keytruda-Patentablauf verliert seinen Schrecken - BofA bleibt bei "buy"Bad Marienberg (www.aktiencheck.de) - Die Aktie von Merck & Co. Inc. (ISIN: US58933Y1055, WKN: A0YD8Q, Ticker-Symbol: 6MK, NYSE-Symbol: MRK) rückt |
Moderna Aktie: William Blair vollzieht die Kehrtwende - Krebs-Durchbruch verändert die Story!Bad Marienberg (www.aktiencheck.de) - Was für eine Woche für Moderna Inc. (ISIN: US60770K1079, WKN: A2N9D9, Ticker-Symbol: 0QF, NASDAQ-Symbol: MRNA)! Erst |
Can Mercks New Drugs Offer Growth Cushion Ahead of Keytruda LOE?MRKs growing pipeline, acquired assets and new product launches are gaining traction as it builds a diversified growth base ahead |
Merck vs. J&J: Which Healthcare Giant Should Investors Choose?JNJs diversified portfolio and pipeline strength offer an edge over MRK as both face patent expiration challenges. |
Cancer vaccine breakthrough at Moderna raises hopes for Scancells melanoma programmeA landmark trial success for Moderna and Mercks cancer vaccine has strengthened the case for Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, |
Merck is a buy as strong cancer drug pipeline offsets Keytruda patent expiration, Morgan Stanley saysMerck, which makes the popular cancer treatment Keytruda, is poised to gain ground as its pipeline drugs get close to |
Moderna and Merck Just Made History With the First mRNA Cancer Vaccine to Succeed in a Phase 3 Trial. Heres What That Means for Investors.The treatment combines an mRNA shot with Mercks Keytruda. |